6-Imino-2-thioxo-pyrimidinones as a new class of dipeptidyl peptidase IV inhibitors

被引:2
|
作者
Jelic, Dubravko [1 ]
Nujic, Krunoslav [1 ]
Stepanic, Visnja [1 ]
Kovacevic, Krunoslav [1 ]
Verbanac, Donatella [1 ]
机构
[1] GlaxoSmithKline Res Ctr Zagreb Ltd, Zagreb 10000, Croatia
关键词
DPP IV inhibitor; Pyrimidinone; Enzyme kinetics; Molecular docking; Cytotoxicity; GENETIC ALGORITHM; VALIDATION; EXPRESSION; THERAPY; DOMAIN;
D O I
10.1007/s00044-010-9314-5
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Dipeptidyl peptidase IV is a glycoprotein which removes N-terminal dipeptides from physiologically relevant polypeptides. An homologous series of 6-imino-2-thioxo-5-{[3,4,5-tris(methyloxy)phenyl]methyl}-2,5-dihydro-4(3H)-pyrimidinones has been tested for inhibition of DPP IV activity. The inhibitory effects at 0.1 mM were observed. Enzyme kinetic studies revealed that compounds inhibit DPP IV activity competitively. According to the molecular docking analysis, the inhibitors are anchored into the DPP IV hydrolytic site by interactions of the pyrimidinone core with Glu206, Tyr662, and Tyr547, with the alkyl chain entering the S1 pocket. We conclude that pyrimidinone-like compounds are a promising new scaffold for reversible inhibition of DPP IV.
引用
收藏
页码:339 / 345
页数:7
相关论文
共 50 条
  • [21] CoMFA and CoMSIA of diverse pyrrolidine analogues as dipeptidyl peptidase IV inhibitors: active site requirements
    Murugesan, Vanangamudi
    Sethi, Nidhi
    Prabhakar, Yenamandra S.
    Katti, Seturam B.
    MOLECULAR DIVERSITY, 2011, 15 (02) : 457 - 466
  • [22] Identification of diverse dipeptidyl peptidase IV inhibitors via structure-based virtual screening
    Li, Cui
    Lu, Weiqiang
    Lu, Chunhua
    Xiao, Wen
    Shen, Xu
    Huang, Jin
    Liu, Guixia
    Tang, Yun
    JOURNAL OF MOLECULAR MODELING, 2012, 18 (09) : 4033 - 4042
  • [23] The highly potent and selective dipeptidyl peptidase IV inhibitors bearing a thienopyrimidine scaffold effectively treat type 2 diabetes
    Deng, Jifeng
    Peng, Li
    Zhang, Guicheng
    Lan, Xiaobing
    Li, Chufang
    Chen, Fuxin
    Zhou, Yayao
    Lin, Zuoxian
    Chen, Ling
    Dai, Renke
    Xu, Hongjiang
    Yang, Ling
    Zhang, Xiquan
    Hu, Wenhui
    EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2011, 46 (01) : 71 - 76
  • [24] Molecular docking and 3D-QSAR studies on β-phenylalanine derivatives as dipeptidyl peptidase IV inhibitors
    Yan-Ke Jiang
    Journal of Molecular Modeling, 2010, 16 : 1239 - 1249
  • [25] Molecular docking and 3D-QSAR studies on β-phenylalanine derivatives as dipeptidyl peptidase IV inhibitors
    Jiang, Yan-Ke
    JOURNAL OF MOLECULAR MODELING, 2010, 16 (07) : 1239 - 1249
  • [26] A thin-layer chromatography-bioautographic method for detecting dipeptidyl peptidase IV inhibitors in plants
    Gu, L. H.
    Liao, L. P.
    Hu, H. J.
    Bligh, S. W. Annie
    Wang, C. H.
    Chou, G. X.
    Wang, Z. T.
    JOURNAL OF CHROMATOGRAPHY A, 2015, 1411 : 116 - 122
  • [27] Cardiometabolic Efficacy of Natural Dipeptidyl Peptidase- IV Inhibitors in Experimental Diabetes with Metabolic Syndrome Rats
    Suman, Rajesh Kumar
    Mohanty, Ipseeta Ray
    Borde, Manjusha K.
    Maheshwari, Ujjawala
    METABOLISM-CLINICAL AND EXPERIMENTAL, 2021, 116 : 15 - 15
  • [28] In silico approaches to predict the potential of milk protein-derived peptides as dipeptidyl peptidase IV (DPP-IV) inhibitors
    Nongonierma, Alice B.
    Mooney, Catherine
    Shields, Denis C.
    FitzGerald, Richard J.
    PEPTIDES, 2014, 57 : 43 - 51
  • [29] A dipeptidyl peptidase IV inhibitory peptide relieves palmitic acid-induced endoplasmic reticulum stress in HepG2 cells independent of inhibiting dipeptidyl peptidase IV activity
    Jin, Ritian
    Ren, Haowei
    Liao, Minhe
    Shang, Jiaqi
    Wang, Dangfeng
    Li, Meng
    Liu, Ning
    FOOD & FUNCTION, 2021, 12 (21) : 10773 - 10782
  • [30] Suspected adverse drug reactions of the type 2 antidiabetic drug class dipeptidyl-peptidase IV inhibitors (DPP4i): Can polypharmacology help explain?
    Jones, Lauren
    Jones, Alan M.
    PHARMACOLOGY RESEARCH & PERSPECTIVES, 2022, 10 (06):